MabVax Therapeutics Holdings, Inc.
http://www.mabvax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MabVax Therapeutics Holdings, Inc.
AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds
A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.
Flagship Plans To Distribute New Fund To About Two Dozen Companies
The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.
Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy
The US FDA approved Day One’s pediatric brain cancer drug Ojemda, ImmunityBio’s bladder cancer immunotherapy Anktiva, an uncomplicated UTI claim for Utility Therapeutics’ Pivya, which has a long history in Europe, and Pfizer’s hemophilia B gene therapy Beqvez.
Why Global Pull Incentives Matter For AMR Drugs
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- MabVax Therapeutics, Inc.
- Telik, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice